Skip to content
Search

Latest Stories

Competition watchdog says PCR testing market needs more regulation

The UK's competition watchdog has advised the government to implement greater regulation on the PCR Covid testing market amid fears that competition alone “will not deliver the right outcomes for consumers”.

The Competition and Markets Authority (CMA) highlighted the risk of a “race to the bottom”, in which testing firms could begin to compete on grounds other than quality with travellers ending up losing out.


Earlier, consumers had complained against the test providers about high charges and poor service. Complainants even said that some providers did not pay refunds and became inaccessible when things went wrong.

The average cost of such a test is £93 in the UK, far higher than in many European countries.

Besides advising the government on the matter, the CMA is already using its powers to act where it can. On August 25, it published an open letter to all PCR test providers warning them to adhere to the consumer law.

Later on September 3, it opened a formal investigation into Expert Medicals, one of the largest providers in the market. It is also considering to launch probe into other companies.

Meanwhile, the CMA review found that “combination of up-front regulation, monitoring and wider sanctions is needed” to deliver right outcome for consumers.

It recommended that the government should create a list of quality providers by “significantly improving the basic standards to qualify for inclusion”.

In addition, an enhanced monitoring system should be brought in to keep track of providers and quickly remove those which fall short of standards.

CMA chief executive Andrea Coscelli said the market needs a “more interventionist approach” backed by monitoring and enforcement to protect consumers.

“Buying a PCR travel test is a lottery. From complaints about dodgy pricing practices, to unfair terms, to failure to provide tests on time or at all, to problems with getting refunds, the experience for some is just not good enough."

Health secretary Sajid Javid said the government has removed 91 providers from Gov.uk and corrected inaccurate prices of 135 private providers, who will be removed from the list if they advertise misleading prices again.

Further, to ensure travel test providers perform as per law, from September 21, “there will be tough new penalties for companies that fail to follow the law, including fixed fines of up to £10,000.”

Javid added: “I am reviewing the recommendations from the Competition and Markets Authority and will outline further changes shortly to ensure consumers are given the best tests at the very best prices.”

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less